Oxytocin Protocol
Neuropeptide hormone studied for social bonding, trust and some anxiolytic/metabolic research angles.
مستوى الأدلة: أدلة ناشئة
توجد أبحاث بشرية و/أو حيوانية وتتراكم، لكن قاعدة الأدلة ليست بعد بحجم دواء معتمد.
الأدلة البشرية: Extensive obstetric clinical trial base for the approved indication; a separate and substantial but distinct behavioral-neuroscience literature exists for social/bonding research, with mixed replication.
الأدلة الحيوانية: Extensive rodent social-behavior literature underpins the "bonding hormone" framing.
المقدمة وآلية العمل
Neuropeptide hormone studied for social bonding, trust and some anxiolytic/metabolic research angles.
Endogenous hypothalamic hormone with an FDA-approved formulation for labor induction/augmentation; the social-bonding and anxiolytic-adjacent research use is a separate, far less regulated context using intranasal or subcutaneous routes.
المستقبلات/الأهداف: Oxytocin receptor (OXTR)
مجالات الاهتمام البحثي
- Social-bonding research
- Anxiolytic-adjacent studies
الفوائد المُبلَّغ عنها في الأبحاث
- Social-bonding research
- Anxiolytic-adjacent studies
نطاق الجرعات البحثية المُبلَّغ عنه
الأرقام أدناه مقتبسة من الأدبيات البحثية المنشورة والمراجع البروتوكولية — وهي تصف ما تمت دراسته، وليست وصفة أو تعليمات شخصية.
النطاق المُبلَّغ عنه: 10–40 IU
التكرار المُبلَّغ عنه: Structured dosing data unavailable
مدة الدورة المُبلَّغ عنها: Structured dosing data unavailable
التصعيد والصيانة: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
الآثار الجانبية
- Nasal irritation (intranasal route)
- Headache
- Flushing
موانع الاستعمال
- Pregnancy (outside supervised obstetric use)
- Cardiovascular disease (theoretical concern)
التفاعلات الدوائية
- Not well characterized for behavioral/wellness research use — obstetric-use interaction data does not directly translate
السلامة
- Approved obstetric use has well-characterized risks (uterine hyperstimulation) not relevant to behavioral research use
- Behavioral/wellness use is comparatively unregulated and less studied for safety
FDA-approved formulations exist for labor/delivery indications; behavioral/wellness research use is a distinct, less-regulated context.
النتائج المتوقعة والمقارنة
It is important not to conflate Oxytocin's FDA-approved obstetric use with its behavioral/wellness research use — these are different evidence bases, doses and routes, and the approval does not extend to the bonding/anxiolytic research application.